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The diagnosis of type I allergy, an IgE-antibody-
mediated hypersensitivity disease affecting more than
25% of the population, is based on the measurement
of allergen-speci®c serum IgE levels and provocation
testing. Whether the determination of allergen-
speci®c serum IgE levels can replace in vivo provoca-
tion testing for allergy diagnosis is a controversial
issue. We used puri®ed recombinant timothy grass
and birch pollen allergens to compare by skin prick
and nasal provocation testing as well as by serology
in vivo sensitivity with antibody-binding capacity in
24 pollen allergic patients and eight control individ-
uals. Results from biologic tests were correlated with
each other and with allergen-speci®c IgE and IgG1-4
levels. IgE-reactive allergens induced immediate skin
and nasal reactions, but the intensity of the allergic
tissue reactions was not correlated with either the
levels of allergen-speci®c IgE or the levels of
allergen-speci®c IgG antibodies. Less frequently
detected allergens with low IgE-binding capacity
were able to induce strong allergic reactions compar-
able to those caused by major allergens with high
IgE-binding capacity. In contrast, skin test and nasal
provocation results were signi®cantly correlated
(r = 0.63, p < 0.01). Our study thus demonstrates on
a molecular level that skin testing provides a better
re¯ection of immediate type respiratory sensitivity
than serologic measurements. These results have
implications for allergy diagnosis and, in particular,
for the selection of relevant allergen components for
speci®c immunotherapy. Key words: diagnosis/IgE/
nasal provocation test/recombinant allergen/rhinomanome-
try/skin prick test/type I allergy. J Invest Dermatol
117:848±851, 2001
T
he immediate symptoms of type I allergy result
from the allergen-induced crosslinking of effector
cell (e.g., mast cell, basophil) bound IgE antibodies,
which leads to the release of histamine and other
in¯ammatory mediators (e.g., leukotriens) (Beaven
and Metzger, 1993). FceRI represents the critical structure for
the activation of effector cells by IgE±allergen complexes and it
is well established that elevated serum IgE levels lead to an
upregulation of FceRI expression (MacGlashan et al, 1998,
1999). The question whether the levels of speci®c IgE
antibodies in serum can act as reliable predictive markers for
clinical sensitivity, however, represents a controversial issue. On
the one hand, several clinical studies indicated no precise
correlation between serum IgE levels and clinical symptoms
(Pelikan, 1983; Bousquet et al, 1987; Rasanen et al, 1994). On
the other hand, it is well established that patients exhibit
increased sensitivity to allergen provocation after seasonal rises
of speci®c IgE levels (Henderson et al, 1975; Naclerio et al,
1997).
Studies regarding the association of serum IgE reactivity and
allergenic activity have been performed mainly with allergen
extracts representing complex and variable mixtures of allergenic
and nonallergenic components. In this study we used de®ned
recombinant allergen molecules instead of allergen extracts to
reinvestigate the association of allergen-speci®c IgE serum levels
with skin and nasal sensitivity.
Two recombinant tree pollen allergens [rBet v 1 (Breiteneder
et al, 1989) and rBet v 2 (Valenta et al, 1991)] and three
recombinant grass pollen allergens [rPhl p 1 (Laffer et al, 1994),
rPhl p 2 (Dolecek et al, 1993), rPhl p 5 (Vrtala et al, 1993)]
were used for in vivo testing (nasal provocation test, skin prick
test) and quantitative in vitro measurement of speci®c antibody
responses (IgE and IgG subclass levels).
In parallel we determined symptoms of allergen-induced
rhinitis by active anterior rhinomanometry. Furthermore,
immediate type skin reactions to recombinant allergens were
measured by skin prick testing. Results from serology and in vivo
provocation testing to de®ned recombinant allergen molecules
were correlated. We discuss possible mechanisms for our
®ndings that allergens with high as well as with low IgE-
binding capacity induced strong allergic reactions and that
results from both in vivo tests (nasal provocation and skin prick
testing), but not from in vitro and in vivo tests, were correlated.
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Furthermore we discuss our ®ndings regarding the possible
application of recombinant allergens for component-resolved
skin test diagnosis and speci®c immunotherapy.
MATERIALS AND METHODS
Patients and control individuals Twenty-four tree and/or grass
pollen allergic patients were included in the study. Patients were selected
on the basis of a positive case history indicative of tree and/or grass
pollen allergy [presence of at least one of the symptoms (rhinitis,
conjunctivitis, or asthma)] during the tree and/or grass pollen season and
elevated serum IgE levels to birch and/or grass pollen extract as
determined by use of the Pharmacia CAP system (Pharmacia, Uppsala,
Sweden).
At the time of the study all patients had stable lung function and there
was no evidence of airway infection. Patients who had received
corticosteroid therapy or antihistamines or who suffered from atopic
dermatitis were excluded from the study.
Five nonallergic individuals and three allergic individuals without
sensitization to the tested allergens were included as controls.
Study design The serum IgE levels speci®c for recombinant allergens
(rPhl p 1, rPhl p 2, rPhl p 5, rBet v 1, and rBet v 2) were determined
by quantitative CAP-RAST measurements (Pharmacia; Table I).
According to the CAP-RAST determinations we selected for each
patient the recombinant allergen yielding the highest and that yielding
the lowest speci®c serum IgE levels for in vivo provocation testing (i.e.,
nasal provocation and skin prick testing). For control purposes, eight
individuals were subjected to provocation testing with three allergens
against which they had no IgE antibodies.
The study was conducted outside the tree and grass pollen season
(winter time) on three different days with a 4 wk interval between study
days. On each study day serum samples were collected, skin prick tests
were performed with both selected recombinant allergens, and nasal
provocation testing was done with one of the two selected recombinant
allergens or placebo, respectively. Nasal provocation tests were performed
in a double-blinded and randomized manner.
The study was approved by the Ethical Committee of the Faculty of
Medicine, University of Vienna, Austria. Each patient and control person
gave written informed consent.
Recombinant allergens Puri®ed recombinant timothy grass pollen
allergens (rPhl p 1, rPhl p 2, rPhl p 5) and recombinant birch pollen
allergens (rBet v 1 and rBet v 2) that had been expressed in Escherichia
coli (Susani et al, 1995; Vrtala et al, 1996; Hoffmann-Sommergruber et al,
1997) were obtained from Biomay (Vienna, Austria).
Determination of total IgE, speci®c IgE, and IgG subclass
levels Total IgE and IgE levels to birch and timothy grass as well as to
rPhl p 1, rPhl p 2, rPhl p 5, rBet v 1, and rBet v 2 were determined by
quantitative CAP-RAST measurements (Pharmacia).
In order to visualize a possible in¯uence of allergen-speci®c IgG
antibodies on IgE binding, IgE enzyme-linked immunosorbent assay
(ELISA) determinations were performed using low allergen concentra-
tions for coating of the plates (25 ng per well). The detection of
allergen-speci®c IgE antibody reactivity by ELISA was performed as
previously described (Laffer et al, 1996). In addition, IgG subclass levels
to puri®ed recombinant allergens were measured by ELISA (Vrtala et al,
1996).
Skin prick testing Skin prick tests were performed with recombinant
allergens diluted in 0.9% sodium chloride solution (5 mg per ml and
20 mg per ml). Sterile 0.9% sodium chloride solution and histamine
hydrochloride (ALK, Horsholm, Denmark) were used for control
purposes. Twenty microliter aliquots of the test solutions were placed on
the patients' forearms with a distance of more than 3 cm between
individual application points. Reactions were recorded 20 min after
testing by photography of patients' forearms and by transferring the
ballpoint pen surrounded weal reaction with a scotch tape to paper. The
maximal longitudinal and transversal diameter of the weal was measured
and the mean diameter of the weal was calculated according to the
formula (D1 + D2)/2. D1 represents the maximal longitudinal and D2
the maximal transversal diameter.
Nasal provocation testing Nasal provocation tests were performed
with two selected recombinant allergens or placebo on one of three
different study days, respectively. To avoid unspeci®c nasal reactions, a
time interval of 4 wk was left between different study days.
On each study day, the baseline level of nasal parameters (nasal ¯ow,
resistance, and ¯ow decrease) was established by active anterior
rhinomanometry without administration of test substances (Bachert,
1997; Melillo et al, 1997). Next, 0.9% sodium chloride solution was
applied to rule out any nonspeci®c hyperreactivity.
Thereafter, the patient received increasing doses of allergen (5 mg per
ml, 10 mg per ml, 20 mg per ml, 40 mg per ml) or placebo in 15 min
intervals. Allergen solutions were administered into one nostril using a
metered pump delivering 15 ml per puff. During application of test
solutions, the patient had to hold his or her breath in full inspiration to
avoid bronchial provocation.
Evaluations were performed 15 min after each provocation by measur-
ing of objective and subjective parameters. Objective parameters were (i)
the number of sneezes, (ii) the weight of nasal secretions (weighing
handkerchiefs), and (iii) the reduction in nasal air¯ow determined by
active anterior rhinomanometry. Subjective parameters comprised (i)
itching, (ii) sneezing, (iii) nasal secretion, (iv) nasal congestion, and (v)
symptoms in other organs (e.g., itching of ears).
For each of the objective and subjective parameters 0±4 points could
be achieved after administration of each of the four allergen concentra-
tions. The points achieved after testing of all four allergen concentrations
were added to yield the total score. When a nasal air¯ow reduction of
60% was exceeded, testing was stopped and full points were given for
the remaining allergen concentrations.
Endpoints and statistical analysis Total scores from nasal
provocation, mean weal diameters (mm), total IgE (kU per liter), speci®c
serum IgE (kUA per liter), and IgG (optical density values) levels
determined for the same allergen on the same study day were compared
using Spearman regression analysis.
RESULTS
Patients with pollen-induced allergic rhinitis exhibit IgE
responses of greatly varying magnitudes to individual
allergen components We studied 24 grass and/or tree pollen
allergic patients suffering from seasonal allergic rhinitis and eight
control individuals without clinical manifestation of pollen allergy.
The group of allergic patients consisted of 14 men and 10 women
with a mean age of 28.4 y. Twenty-three of the 24 patients also had
allergic conjunctivitis and 12 patients suffered from asthma. RAST
serology (CAP, Pharmacia) showed that all 24 patients contained
IgE antibodies to timothy grass pollen extract and 16 patients had
IgE antibodies to birch pollen extract. All 24 patients displayed IgE
antibodies to Phl p 1, 22 reacted with Phl p 2, and 22 patients
contained IgE against Phl p 5. Bet v 1 was recognized by 12 of 16
birch pollen allergic patients and 10 of these patients also reacted
with Bet v 2. Patients mounted widely varying speci®c IgE
levels to the recombinant allergen components tested (rPhl p 1,
2.16±65.7 kUA per liter, average 21.0 kUA per liter; rPhl p 2,
0.40±42.3 kUA per liter, average 11.3 kUA per liter; rPhl p 5,
1.57±83.3 kUA per liter, average 21.8 kUA per liter; rBet v 1,
0.45±98.1 kUA per liter, average 29.1 kUA per liter; rBet v 2,
0.40±11.5 kUA per liter, average 4.62 kUA per liter) (Table I).
The allergenic activity of individual allergen components
cannot be predicted by serology: allergens with low IgE-
binding capacity can induce strong allergic reactions In
Fig 1 we compare allergen-speci®c IgE levels (x axis, kUA per
Table I. Comparison of average results obtained by
serology, skin testing and nasal provocation with different








Phl p 1 24.2 19.6 5.0 (n = 5)
Phl p 2 4.47 46.3 14.0 (n = 11)
Phl p 5 22.4 41.8 11.8 (n = 19)
Bet v 1 22.5 50.5 14.2 (n = 5)
Bet v 2 3.44 39.1 11.1 (n = 8)
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liter) with the results of skin prick testing (y axis, mean weal
diameters of skin reactions), and in Fig 2 with results from nasal
provocation testing (y axis, points) by scatter plotting. We found no
correlation between allergen-speci®c IgE levels and mean weal
diameters (r = 0.1) (Fig 1). Likewise, allergen-speci®c IgE levels
and the scores achieved in nasal provocation tests were not
correlated (r = 0.2) (Fig 2).
The lack of correlation between allergen-speci®c IgE levels and
biologic test results is also emphasized by the observations (i) that
the highest average IgE levels were directed against recombinant
timothy grass pollen allergen, rPhl p 1 (24.2 kUA per liter), which
induced the weakest average biologic reactions in both provocation
tests (19.6 points, 5 mm MD) (Table I), and (ii) that the two
allergens with low average IgE-binding capacity (rPhl p 2,
4.47 kUA per liter, 14.0 mm MD, 46.3 points; rBet v 2,
3.44 kUA per liter, 11.1 mm MD, 39.1 points) induced biologic
reactions comparable to those induced by allergens with high
average IgE-binding capacity (rPhl p 5, 22.4 kUA per liter,
11.8 mm MD, 41.8 points; rBet v 1, 22.5 kUA per liter, 14.2 mm
MD, 50.5 points) (Table I).
These results indicate that allergens that in quantitative IgE assays
bind low levels of speci®c IgE can induce strong clinical symptoms.
The allergenic potency of recombinant allergens can be
de®ned by skin prick testing as well as by nasal provocation
testing: the results of both in vivo tests are signi®cantly
correlated Scatter plot comparison of the results obtained by
skin prick testing (mean weal diameters) with those gained by nasal
provocation testing (scores) revealed a strong and signi®cant
correlation (r = 0.63, p < 0.01) (Fig 3). Thus, the biologic
activity (i.e., the potency to induce clinical symptoms) of a given
allergen was equally well de®ned by skin prick testing and by nasal
provocation testing (Fig 3, Table I). Individuals who were tested
with allergens against which they contained no IgE antibodies
displayed no reaction in skin prick or nasal provocation tests.
Lack of evidence that allergen-speci®c IgG antibodies are
responsible for the discrepancy between IgE levels and
biologic reactions in the tested patients The following two
observations suggest that the lack of correlation between allergen-
speci®c IgE levels and results obtained by biologic tests in our study
group cannot be explained by the presence of allergen-speci®c IgG
antibodies. (i) No correlation between allergen-speci®c IgG
subclass levels, IgE levels, and biologic test results was observed
(data not shown). (ii) When determinations of allergen-speci®c IgE
were carried out with low concentrations of allergens allowing
competition of IgG, similar results to determinations carried out in
allergen excess were obtained (r = 0.8; data not shown).
DISCUSSION
Using recombinant pollen allergen molecules we found no
correlation between the amount of allergen-speci®c serum IgE
levels and results from nasal provocation and skin prick tests.
Allergens with low IgE-binding capacity (rPhl p 2, rBet v 2) were
able to induce biologic reactions comparable to those induced by
allergens with high IgE-binding capacity (rPhl p 5, rBet v 1) and
caused even stronger reactions than rPhl p 1, a major allergen that is
recognized by more than 95% of grass pollen allergic patients.
These results demonstrate that allergen extracts currently used for
diagnosis and therapy contain several allergen components of which
some can induce much stronger allergic reactions than others. Thus
the IgE-binding capacity of a given allergen cannot be used to
predict its allergenic activity.
We must therefore consider that factors other than the IgE-
binding capacity of a particular allergen can in¯uence the extent of
the allergic tissue reaction induced by the molecule. Results
obtained with recombinant allergen molecules in our study show
that three suspected possibilities for the discrepancy between
serology and clinical sensitivity are not suf®cient to explain the
phenomenon. The ®rst possibility, that the number and/or
sensitivity of allergic effector cells in the target organs (e.g.,
respiratory tract, skin) dictate the intensity of the allergic reaction,
cannot explain the different responsiveness to various allergen
components.
Figure 3. Relation between mean diameter of skin reactions and
points obtained in nasal provocation tests.
Figure 1. Relation between speci®c IgE levels and mean
diameter of skin reactions.
Figure 2. Relation between speci®c IgE levels and points
obtained in nasal provocation tests.
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The second explanation, that allergen-speci®c IgG either
competed with IgE or, via co-crosslinking, inactivated effector
cells, is also not supported by our data. We found that allergen-
speci®c IgG1-4 levels were not correlated with allergen-speci®c IgE
levels nor with nasal or skin sensitivity. When ELISA plates were
coated with low amounts of allergens to allow competition of
allergen-speci®c IgG with IgE binding, comparable results were
obtained to the determinations performed in allergen excess, and
the correlation between serology and clinical sensitivity did not
improve. We must admit, however, that an experimental setup that
would allow investigation of the possibility that co-crosslinking of
effector cell bound IgE and IgG could have caused the discrepancy
between serology and clinical sensitivity in the nose and skin has
not yet been available to us.
The third assumption, that the biologic function of a particular
allergen could be related to its allergenic activity in the nose or skin,
cannot be supported by our results. Allergens with possible RNAse
(Bet v 1, Phl p 5) or protease/expansin (Phl p 1) activity in general
did not induce stronger tissue reactions than allergens without
enzymatic activity [e.g., Bet v 2, pro®lin, an actin-binding
ubiquitous cytoskeletal protein (Valenta et al, 1991); Phl p 2, an
allergen mimicking the structure of an immunoglobulin domain
(De Marino et al, 1999)].
We therefore propose that (i) the number and/or density of IgE
epitopes on a particular allergen, (ii) the af®nity/avidity of IgE
antibodies, (iii) the recognition of allergens by certain IgE variants
and/or (iv) the structural orientation of IgE epitopes on an allergen
can in¯uence the magnitude of the effector cell response.
In summary our data show that allergic patients can exhibit a
widely varying sensitivity to individual allergen components that
cannot be predicted by quantitative IgE serology alone. Our
®nding that skin sensitivity showed a good correlation with nasal
sensitivity indicates that skin testing with allergen molecules may be
useful to predict the potential of allergens to induce respiratory
symptoms and thus help to identify the most relevant allergen
components for speci®c immunotherapy. New forms of
component-resolved immunotherapy that are based on the use of
synthetic and genetically modi®ed allergens with reduced allergenic
activity are currently being developed and can then be tailored to
the patients' sensitization pro®le established by component-
resolved allergy diagnosis (Valenta and Kraft, 2001).
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